CVS Health (CVS) Set to Post Earnings on Wednesday

CVS Health (NYSE:CVS) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $1.66 per share and revenue of $104.72 billion for the quarter. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same period last year, the firm earned $1.81 earnings per share. CVS Health’s revenue was up 7.3% on a year-over-year basis. On average, analysts expect CVS Health to post $8.02 EPS for the current fiscal year and $8.51 EPS for the next fiscal year.

CVS Health Price Performance

NYSE CVS opened at $91.11 on Wednesday. The company has a fifty day moving average of $91.46 and a two-hundred day moving average of $88.62. The company has a market capitalization of $116.53 billion, a PE ratio of 24.10 and a beta of 0.60. CVS Health has a 1 year low of $69.51 and a 1 year high of $110.68.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be issued a $0.6650 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health’s payout ratio is presently 70.37%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expected to benefit from a recovery in Aetna’s margins and continued earnings improvement. Its full-year 2026 outlook calls for EPS of approximately $7.90–$8.10, supporting the view that profitability is recovering after several difficult years. Should You Buy CVS Health Stock While It’s Under $100?
• Positive Sentiment: The company is expanding its retail assortment to include more Pokémon products, collectibles, toys and seasonal merchandise. Management expects adult demand for collectibles to create additional front-store sales opportunities. CVS wants to sell more Pokémon, collectibles
• Neutral Sentiment: Investors are awaiting CVS’s third-quarter 2026 report. Aetna margin recovery and digital investments could support results, but the company continues to face 340B-related pressure and declining membership, making the earnings outlook mixed. CVS Health Q3 Earnings Preview
• Neutral Sentiment: A shareholder-law firm is soliciting CVS investors regarding potential breaches of fiduciary duties. The notice does not establish wrongdoing, but it could add headline and litigation risk. Shareholder fiduciary-duty inquiry
• Negative Sentiment: CVS pharmacy workers in Rhode Island rallied over staffing and contract issues, highlighting potential labor disruption, wage pressure and service-quality concerns. CVS workers in Rhode Island rally
• Negative Sentiment: Health insurers are challenging Medicaid rating requirements in Georgia. Any unfavorable outcome could increase compliance costs or pressure reimbursement economics for insurers, including CVS’s Aetna business. Georgia Medicaid rating challenges

Analyst Ratings Changes

A number of analysts recently issued reports on CVS shares. Argus upped their target price on CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. Wells Fargo & Company lifted their price target on CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. HSBC reaffirmed a “hold” rating and set a $103.00 price target on shares of CVS Health in a research report on Monday, July 6th. Wall Street Zen cut CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Finally, Truist Financial increased their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Twenty analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

CVS Health Company Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.